Meeting
2023 ASCO Annual Meeting
Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial).
Authors
Ji-Jung Jung
Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea
Ji-Jung Jung , Soo-Yeon Kim , Jiwon Koh , Jong-Ho Cheun , Min Kyoon Kim , Jai Min Ryu , Tae-Kyung Yoo , Seho Park , Hee-Chul Shin , Sung Gwe Ahn , Woosung Lim , Sang Eun Nam , Min Ho Park , Jeeyeon Lee , Taewoo Kang , Ku Sang Kim , Hyun Jo Youn , Yoo Seok Kim , Wonshik Han , Han-Byoel Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Local-Regional Therapy
Clinical Trial Registration Number
NCT05505357
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS627)
DOI
10.1200/JCO.2023.41.16_suppl.TPS627
Abstract #
TPS627
Poster Bd #
451a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Artificial intelligence (AI) –based machine learning models (ML) for predicting pathological complete response (pCR) in patients with hormone receptor (HoR) –positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT): A retrospective cohort study.
First Author: Luca Mastrantoni
Poster
2012 ASCO Annual Meeting
Magnetic resonance imaging (MRI) evaluation of pathologic complete response (pCR) in different breast cancer subtypes after neoadjuvant chemotherapy (NAC).
First Author: Lucia Gonzalez-Cortijo
Poster
2020 ASCO Virtual Scientific Program
Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer (TNBC) with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21).
First Author: In Hae Park
Poster
2018 ASCO Annual Meeting
Predicting neo-adjuvant chemotherapy response from pre-treatment breast MRI using machine learning and HER2 status.
First Author: Nathaniel Braman